Publications de Ioanna Keklikoglou

Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Kras-mutant NSCLC

Michele De Palma, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Amaia Martinez Usatorre, Alan Nicolas Thierry Guichard

AMER ASSOC CANCER RESEARCH2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Michele De Palma, Nadine Fournier, Bruno Torchia, Etienne Meylan, Chiara Cianciaruso, Sina Nassiri, Ioanna Keklikoglou, Ece Kadioglu, Gael Luis Boivin, Amaia Martinez Usatorre

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Ioanna Keklikoglou, Michele De Palma, Mario Leonardo Squadrito, Chiara Cianciaruso, Esra Güç, Alan Nicolas Thierry Guichard, Antonino Cassarà

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can ...

2019

Periostin Limits Tumor Response to VEGFA Inhibition

Michele De Palma, Ioanna Keklikoglou, Ece Kadioglu, Axel Bellotti

Resistance to antiangiogenic drugs limits their applicability in cancer therapy. Here, we show that revascularization and progression of pancreatic neuroendocrine tumors (PNETs) under extended vascular-endothelial growth factor A (VEGFA) blockade are depen ...

2018

Perivascular M2 macrophages stimulate tumor relapse after chemotherapy

Michele De Palma, Ioanna Keklikoglou

Tumor relapse after chemotherapy-induced regression is a major clinical problem, because it often involves inoperable metastatic disease. Tumor-associated macrophages (TAM) are known to limit the cytotoxic effects of chemotherapy in preclinical models of c ...

American Association for Cancer Research2015

Cancer: Metastasis risk after anti-macrophage therapy

Michele De Palma, Ioanna Keklikoglou

Nature Publishing Group2014

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade

Michele De Palma, Ioanna Keklikoglou, Céline Wyser Rmili, Ece Kadioglu, Nicolo Rigamonti

Angiopoietin-2 (ANG2/ANGPT2) is a context-dependent TIE2 receptor agonist/antagonist and proangiogenic factor. Although ANG2 neutralization improves tumor angiogenesis and growth inhibition by vascular endothelial growth factor (VEGF)-A signaling blockade, ...

Elsevier2014